|
Predictors
|
HR
|
95% CI
|
P
value
|
|---|
|
Comorbidities
| | | |
|
Immunocompromised hosts
|
1.29
|
0.87–1.91
|
0.915
|
|
Malignancy
|
1.37
|
0.92–2.06
|
0.122
|
|
Septic shock
|
2.66
|
1.71–4.12
|
<0.001
|
|
Severity score at VAP onset
| | | |
|
SAPS II >45
|
1.58
|
1.01–2.46
|
0.045
|
|
SOFA >5
|
3.33
|
1.94–5.72
|
<0.001
|
|
Groups of A. baumannii
| | | |
|
DS
|
1
| | |
|
MDR
|
1.03
|
0.44–2.45
|
0.936
|
|
XDR
|
1.64
|
0.74–3.64
|
0.220
|
|
PDR
|
1.41
|
0.47–4.23
|
0.537
|
|
Empirical antibiotic treatment
| | | |
|
Inappropriate
|
1.53
|
1.08–2.20
|
0.016
|
-
SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ Failure Assessment, DS drug-sensitive, MDR multidrug-resistant, XDR extensively drug-resistant, PDR pandrug-resistant A. baumannii, VAP ventilator-associated pneumonia.
